Curis Inc (CRIS): Total Liabilities
$14.50M
As of 2025-12-31
$14.28M
As of 2026-06-30
-38.5%
3-year compound annual growth
-27.8%
5-year compound annual growth
-7.1%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.50M | -69.3% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $47.26M | -18.0% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $57.61M | -7.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $62.30M | -13.0% | 2024-02-08, Balance as of period end |
| 2021-12-31 | $71.59M | -2.8% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $73.69M | +6.8% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $69.02M | +64.9% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $41.86M | -16.0% | 2020-03-19, Balance as of period end |
| 2017-12-31 | $49.80M | +74.8% | 2019-03-26, Balance as of period end |
| 2016-12-31 | $28.49M | -6.5% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $30.45M | -7.2% | 2017-03-09, Balance as of period end |
| 2014-12-31 | $32.83M | -7.3% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $35.42M | -0.2% | 2015-02-24, Balance as of period end |
| 2012-12-31 | $35.50M | +327.5% | 2014-03-13, Balance as of period end |
| 2011-12-31 | $8.30M | +61.8% | 2013-03-13, Balance as of period end |
| 2010-12-31 | $5.13M | n/a | 2012-02-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
Compare CRIS, TSHA, ACOG, TCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗